glp-1 agonists with cardiovascular benefit The Physiology of Glucagon-like Peptide-1 Receptor Agonists: From Macro-Level Outcomes to Micro-Level Mechanisms Cardiovascular, mortality, and kidney outcomes

Originally used to treat type 2 diabetes, GLP1 medications are now also widely used for weight management

Berlin-Chemie and Roche (speakers bureau)

After Pfizers initial $7.3 billion all-cash deal was announced in September 2025, Danish rival Novo Nordisk unexpectedly submitted a competing takeover bid, sparking an intense bidding war

Managing GI Side Effects# Regardless of the specific drug, several strategies can mitigate GI adverse events: Slow titration: Following or extending the recommended dose escalation schedule Dietary modification: Smaller meals, avoiding high-fat foods, eating slowly Timing: Taking the injection (or pill) at a consistent time, often in the evening Hydration: Maintaining adequate fluid intake to offset effects of reduced food intake Anti-emetics: Short-term use during dose escalation if needed What to Watch# Ecnoglutide and CT-388 Phase 3 data -- Will the tolerability advantage of biased agonism hold in larger, longer trials

Before starting therapy, its essential to assess a patients readiness for behavior change and review both contraindications and precautions to ensure safe and appropriate use